AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble urokinase-type plasminogen activator receptor (suPAR) in Stage C/D
Number of subjects: 1235
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) in Stage C/D
Number of subjects: 1235
Study 35942508 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher biomarker concentrations in Stages A/B and C/D
Number of subjects: 1235
Study 35942530 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 μM Lacripep
Number of subjects: 204
Study 35942530 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 μM Lacripep
Number of subjects: 204
Study 35942530 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 204
Study 35942675 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of GJA1 variants
Number of subjects: 966
Study 35942675 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker intake
Number of subjects: 966
Study 35942675 — intervention group
Group type: COMPARATOR
Intervention: Atrial fibrillation
Number of subjects: 966
Study 35942675 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction >50%
Number of subjects: 966
Study 35943114 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 4028
Study 35943168 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision cancer medicine (PCM)
Number of subjects: 0
Study 35943168 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 35943272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged weaning group
Number of subjects: 915
Study 35943448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-oxalate diet (LOD) for 3 weeks
Number of subjects: 30
Study 35943448 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 35943786 — intervention group
Group type: EXPERIMENTAL
Intervention: PointCheck (noninvasive device for neutropenia screening)
Number of subjects: 154
Study 35943868 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Number of subjects: 0
Study 35943899 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin (BI) plus oral hypoglycemic drugs (OADs)
Number of subjects: 297
Study 35943899 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin plus oral hypoglycemic drugs (OADs)
Number of subjects: 297
Study 35944181 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing for DHCWs
Number of subjects: 4
Study 35944181 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing for patients
Number of subjects: 4
Study 35944181 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-based (LAB) testing for DHCWs
Number of subjects: 4
Study 35944181 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-based (LAB) testing for patients
Number of subjects: 4
Study 35944273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 0
Study 35944349 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port thoracoscopic sympathicotomy (SPTS) on the left side at the third rib (R3)
Number of subjects: 8
Study 35944349 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port thoracoscopic sympathicotomy (SPTS)
Number of subjects: 8
Study 35944376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-Cued Eating (GCE)
Number of subjects: 30
Study 35944767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) treatment
Number of subjects: 200
Study 35944889 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD implantation
Number of subjects: 1637
Study 35944904 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 278
Study 35945122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic imaging in patients with PD
Number of subjects: 50
Study 35945122 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50
Study 35945244 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel with carboplatin followed by concomitant FHX (infusional 5-fluorouracil, hydroxyurea and twice-daily radiation therapy) plus nab-paclitaxel at a dose of 100 mg/m
Number of subjects: 48
Study 35945244 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel with FHX
Number of subjects: 48
Study 35945470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic blood pressure goal <120 mmHg)
Number of subjects: 9361
Study 35945470 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering (<140 mmHg)
Number of subjects: 9361
Study 35945470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 9361
Study 35945477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy (20% male vs 14% female)
Number of subjects: 3159
Study 35945477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor therapy (69% male vs 62% female)
Number of subjects: 3159
Study 35945477 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (17% male vs 11% female)
Number of subjects: 3159
Study 35945477 — intervention group
Group type: COMPARATOR
Intervention: 30-day mortality (50% male vs 49% female)
Number of subjects: 3159
Study 35945477 — intervention group
Group type: COMPARATOR
Intervention: 30-day mortality after adjustment for disease severity, frailty, age and treatment limitations
Number of subjects: 3159
Study 35945517 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.10-0.20 mg/kg/week
Number of subjects: 510
Study 35945517 — intervention group
Group type: COMPARATOR
Intervention: PEG-rhGH 0.10-0.14 mg/kg/week (Group A)
Number of subjects: 510
Study 35945517 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.15-0.20 mg/kg/week (Groups B, C, D)
Number of subjects: 510
Study 35945517 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH based on IGF-1 status
Number of subjects: 510
Study 35945517 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhGH
Number of subjects: 510
Study 35945547 — intervention group
Group type: EXPERIMENTAL
Intervention: E7090 (tasurgratinib), administered once daily as an oral single agent in 28-day cycles.
Number of subjects: 45
Study 35945547 — intervention group
Group type: EXPERIMENTAL
Intervention: E7090 (tasurgratinib)
Number of subjects: 45
Study 35945605 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT) protocol based on achieving an optimal stroke volume, systolic blood pressure > 90 mmHg, and individualized cardiac index.
Number of subjects: 551
Study 35945605 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT) protocol
Number of subjects: 551
Study 35945605 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment (Control Group)
Number of subjects: 551
Study 35945611 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentor intervention
Number of subjects: 20
Study 35945625 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation programme
Number of subjects: 42
Study 35945943 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-HAND Program
Number of subjects: 40
Study 35945943 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study 35946431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib with lenalidomide and methylprednisolone
Number of subjects: 49
Study 35946927 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin fixed-dose combination (FDC)
Number of subjects: 1146
Study 35947027 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy in the adjuvant setting
Number of subjects: 0
Study 35947027 — intervention group
Group type: EXPERIMENTAL
Intervention: First-in-class, highly selective inhibitor of KRAS G12C
Number of subjects: 0
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: Betamimetics
Number of subjects: 13697
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: COX inhibitors
Number of subjects: 13697
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 13697
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulphate
Number of subjects: 13697
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin receptor antagonists
Number of subjects: 13697
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: Nitric oxide donors
Number of subjects: 13697
Study 35947046 — intervention group
Group type: COMPARATOR
Intervention: Combinations of tocolytics
Number of subjects: 13697
Study 35947087 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion
Number of subjects: 0
Study 35947304 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-directed transgastric ERCP (EDGE)
Number of subjects: 36
Study 35947304 — intervention group
Group type: COMPARATOR
Intervention: Other options offered (Laparoscopy-assisted ERCP, Single-Balloon ERCP, Percutaneous drainage)
Number of subjects: 36
Study 35947435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo MRI angiography with contrast agent injection in the umbilical cord
Number of subjects: 100
Study 35947992 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPROSLE (omic-based analytical workflow)
Number of subjects: 6850
Study 35947992 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPROSLE
Number of subjects: 6850
Study 35948252 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD group B (high pulmonary symptoms)
Number of subjects: 2664
Study 35948252 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD group D (high pulmonary symptoms and high COPD exacerbation risk)
Number of subjects: 2664
Study 35948252 — intervention group
Group type: COMPARATOR
Intervention: Control group (ever smokers without COPD)
Number of subjects: 2664
Study 35948291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in the surgeon and communication style during preoperative consultation and postoperative encounters.
Number of subjects: 80
Study 35948291 — intervention group
Group type: EXPERIMENTAL
Intervention: New strategies to improve language practices and surgeon-patient interaction.
Number of subjects: 80
Study 35948294 — intervention group
Group type: COMPARATOR
Intervention: Full checklist completion
Number of subjects: 5677
Study 35948294 — intervention group
Group type: COMPARATOR
Intervention: Designation of a checklist coordinator
Number of subjects: 5677
Study 35948294 — intervention group
Group type: COMPARATOR
Intervention: Incomplete checklist completion
Number of subjects: 5677
Study 35948301 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-OSA sleep disorders
Number of subjects: 200
Study 35948301 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report, capacity assessments, and performance measures
Number of subjects: 200
Study 35948301 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist actigraphy, sleep diaries, overnight oximetry, sleep disorders screening questionnaires
Number of subjects: 200
Study 35948301 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-meter walk test, Stroke Impact Scale, Barthel index, modified Rankin scale
Number of subjects: 200
Study 35948301 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg accelerometry, community trips via GPS data and activity logs
Number of subjects: 200
Study 35948378 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening for SARS-CoV-2 among hospitalized patients
Number of subjects: 15690
Study 35948378 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with a positive test
Number of subjects: 15690
Study 35948604 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 35948604 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 35948604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 35948844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 1255
Study 35948879 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISA tri 839MP multifocal IOL
Number of subjects: 36
Study 35948919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential epirubicin and docetaxel monotherapy
Number of subjects: 51
Study 35948956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 26318
Study 35948956 — intervention group
Group type: COMPARATOR
Intervention: Occasional meat-eaters
Number of subjects: 26318
Study 35948956 — intervention group
Group type: COMPARATOR
Intervention: Pescatarians
Number of subjects: 26318
Study 35949152 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated anxiety
Number of subjects: 897
Study 35949152 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated depression
Number of subjects: 897
Study 35949152 — intervention group
Group type: COMPARATOR
Intervention: Unemployed patients
Number of subjects: 897
Study 35949152 — intervention group
Group type: COMPARATOR
Intervention: Patients with a disability pension
Number of subjects: 897
Study 35949152 — intervention group
Group type: COMPARATOR
Intervention: Patients with a disability pass
Number of subjects: 897
Study 35949152 — intervention group
Group type: COMPARATOR
Intervention: Patients diagnosed 2 to <5 years and ≥5 years
Number of subjects: 897
Study 35949152 — intervention group
Group type: COMPARATOR
Intervention: Patients with thoracic STS
Number of subjects: 897
Study 35949152 — intervention group
Group type: COMPARATOR
Intervention: Patients with progressive disease
Number of subjects: 897
Study 35949290 — intervention group
Group type: EXPERIMENTAL
Intervention: GNS561 200 mg BID
Number of subjects: 26
Study 35949290 — intervention group
Group type: EXPERIMENTAL
Intervention: GNS561 50-400 mg Q3W
Number of subjects: 26
Study 35949290 — intervention group
Group type: EXPERIMENTAL
Intervention: GNS561
Number of subjects: 26
Study 35949358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (GIP/GLP-1R unimolecular dual agonist)
Number of subjects: 13000
Study 35949367 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO and its precursors (choline, betaine, carnitine) in maternal and cord plasma
Number of subjects: 1496
Study 35950205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily for 12 months
Number of subjects: 13
Study 35950205 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily after switching from nilotinib
Number of subjects: 13
Study 35950205 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (after switch from nilotinib)
Number of subjects: 13
Study 35950267 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring programme
Number of subjects: 745
Study 35950267 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 745
Study 35950603 — intervention group
Group type: EXPERIMENTAL
Intervention: AdAPT-001 monotherapy
Number of subjects: 0
Study 35950603 — intervention group
Group type: EXPERIMENTAL
Intervention: AdAPT-001 combined with checkpoint inhibitor
Number of subjects: 0
Study 35950611 — intervention group
Group type: EXPERIMENTAL
Intervention: CTPA
Number of subjects: 149
Study 35950621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multikinase inhibitors
Number of subjects: 0
Study 35950901 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0
Study 35950901 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35951488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural adaptation of the Adult Day Service Plus intervention for Hispanic/Latino caregivers
Number of subjects: 0
Study 35951553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal group meetings to identify treatment goals and features
Number of subjects: 51
Study 35951553 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in the healthcare team
Number of subjects: 51
Study 35951553 — intervention group
Group type: EXPERIMENTAL
Intervention: Having good information about options
Number of subjects: 51
Study 35951553 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term outlook
Number of subjects: 51
Study 35951553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health, quality of life, family and friends, recovery, homecare, and the process of decision-making
Number of subjects: 51
Study 35951576 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 6 (gradient color feedback, world-locked, speed relative to player, disappears over time)
Number of subjects: 25
Study 35951576 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 5 and 6 (world-locked and speed equal to player speed)
Number of subjects: 25
Study 35951576 — intervention group
Group type: COMPARATOR
Intervention: Other scenarios (not specified)
Number of subjects: 25
Study 35951745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 62
Study 35951745 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study 35952327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, and Ibrutinib (RLI)
Number of subjects: 60
Study 35952327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, and Ibrutinib (RLI) followed by chemotherapy
Number of subjects: 60
Study 35952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild asthma patients experiencing exacerbations
Number of subjects: 2004
Study 35952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbations
Number of subjects: 2004
Study 35952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 2004
Study 35952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control
Number of subjects: 2004
Study 35952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization
Number of subjects: 2004
Study 35952707 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalated locoregional radiotherapy according to risk group guidelines (no chest wall radiotherapy in low-risk, local radiotherapy in intermediate-risk, locoregional radiotherapy in high-risk)
Number of subjects: 838
Study 35952707 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to study guideline for radiotherapy
Number of subjects: 838
Study 35952709 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg twice daily for two 14-day courses before and during chemoradiotherapy.
Number of subjects: 38
Study 35952709 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib plus neoadjuvant chemoradiotherapy.
Number of subjects: 38
Study 35952709 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management (control group).
Number of subjects: 38
Study 35952840 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester docosahexaenoic acid and eicosapentaenoic acid supplementation
Number of subjects: 1535
Study 35952840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 1535
Study 35952840 — intervention group
Group type: COMPARATOR
Intervention: First-trimester dietary sources of docosahexaenoic acid and eicosapentaenoic acid (among women with no supplementation)
Number of subjects: 1535
Study 35953136 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 PH
Number of subjects: 1193
Study 35953136 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 1-3 PH
Number of subjects: 1193
Study 35953136 — intervention group
Group type: EXPERIMENTAL
Intervention: WSPH groups 1-4
Number of subjects: 1193
Study 35953136 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 PH
Number of subjects: 1193
Study 35953136 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1, 3, and 4 PH
Number of subjects: 1193
Study 35953136 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 participants
Number of subjects: 1193
Study 35953259 — intervention group
Group type: EXPERIMENTAL
Intervention: IACA! programme (harm reduction programme based on psychosocial recovery)
Number of subjects: 100
Study 35953672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered porcine construct, double crosslinked (BPCDX)
Number of subjects: 20
Study 35953715 — intervention group
Group type: EXPERIMENTAL
Intervention: GAWMerge protocol for combining genotypes from arrays and whole-genome sequencing
Number of subjects: 0
Study 35953715 — intervention group
Group type: EXPERIMENTAL
Intervention: GAWMerge protocol
Number of subjects: 0
Study 35953737 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Follow-Up (DFU)
Number of subjects: 597
Study 35953737 — intervention group
Group type: COMPARATOR
Intervention: Telephone Follow-Up (TFU)
Number of subjects: 597
Study 35953839 — intervention group
Group type: EXPERIMENTAL
Intervention: RESHAPE training (service users shared photographic recovery narratives and facilitated social contact)
Number of subjects: 28
Study 35953839 — intervention group
Group type: COMPARATOR
Intervention: Standard mhGAP training
Number of subjects: 28
Study 35953839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training arms (RESHAPE and standard mhGAP)
Number of subjects: 28
Study 35954244 — intervention group
Group type: EXPERIMENTAL
Intervention: CHST7 methylation status
Number of subjects: 0
Study 35954555 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP) consisting of exercise, education, and cognitive-behavioral therapy for 8 weeks
Number of subjects: 132
Study 35954555 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP)
Number of subjects: 132
Study 35957722 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-staged hybrid operation (HO) group
Number of subjects: 132
Study 35957722 — intervention group
Group type: COMPARATOR
Intervention: Multi-staged operation (MO) group
Number of subjects: 132
Study 35957743 — intervention group
Group type: EXPERIMENTAL
Intervention: Central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) measurements in men.
Number of subjects: 1172
Study 35957743 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriole-to-venule ratio (AVR) measurements.
Number of subjects: 1172
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody positive participants
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk for COVID-19 by GP
Number of subjects: 1082
Study 35957800 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 44 years
Number of subjects: 1082